Real-world study of lazertinib as second-line or greater treatment in advanced non-small cell lung cancer.

Thorac Cancer · 2024 · PMC11219289 · PMID 38798190

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Patients with TP53 showed a trend toward worse PFS rate when compared to patients who did not have TP53, but no statistical significance was present.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.